Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.60
Bid: 3.60
Ask: 4.02
Change: -0.19 (-5.01%)
Spread: 0.42 (11.667%)
Open: 3.60
High: 3.60
Low: 3.60
Prev. Close: 3.79
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New distribution agreement with Nutrien

23 May 2022 07:00

RNS Number : 3452M
Plant Health Care PLC
23 May 2022
 

RNS

23 May, 2022

 

 

Plant Health Care plc

("Plant Health Care" or the "Company")

 

Long-term commercial agreement signed with Nutrien Ag Solutions for PHC's Saori® soybean seed treatment

 

Plant Health Care® (AIM: PHC.L), a leading provider of novel patent-protected biological products to global agriculture markets, announces its partnership with Nutrien Soluções Agrícolas ("Nutrien") for its Saori® soybean seed treatment is progressing ahead of expectations in Brazil.

 

Highlights

 

· PHC and Nutrien have now signed a five-year commercial agreement under which Plant Health Care will supply Saori for Nutrien's use on soybeans in Brazil.

· Saori was launched by Nutrien in September 2021; grower response has been very positive.

· PHC's revenue from sales of Saori to Nutrien is expected to exceed US$750k in the first half of 2022, growing to more than US$5m by 2025.

· Nutrien expects to treat approximately 150,000 hectares of soybeans in 2022, expanding to more than one million hectares by 2025.

· The Total Addressable Market for Saori in Brazil in 2022 is estimated at 40 million hectares of soybean fields.

· Saori-treated fields were healthier and more robust, with lower incidence of disease compared to untreated fields. 

· In PHC's own trials, the average yield increase was almost 10%.

 

Background

Plant Health Care has invested more than $25 million in its PREtec peptide technology platform ("Vaccines for Plants"). PREtec is a novel class of technology which stimulates the plant to defend itself. Derived from natural proteins, PREtec is an environmentally friendly approach to protecting crops and is compatible with mainstream agricultural practices. 

 

The Company plans major launches of PREtec products every year. Saori was the first product to be launched from the PREtec platform and is based on Plant Health Care's PHC279, a novel technology that makes soy plants healthier, improves resistance to multiple diseases and increases yield.

 

Ongoing field trials in Brazil with more than 200 soybean farmers in the 2021/22 season confirmed the benefits of Saori. Initial reports indicated Saori-treated fields were healthier and more robust, with lower incidence of disease compared to untreated fields. In PHC's own trials, the average yield increase was almost 10% and more than 90% of the Saori-treated fields showed a positive response.

 

With 40 million hectares (99 million acres) of soybeans planted in Brazil, this is a very large opportunity. Brazilian soybean farmers spent US$2.85 billion on disease control in the 2019/20 season. Saori offers a highly cost-effective tool to farmers to reduce spend on disease control and to increase yield.

 

 

Chris Richards, CEO of Plant Health Care said, ‟I am very pleased to see the positive response of Brazilian soybean growers to Nutrien's initial launch of Saori during the 2021/22 season. Building on that positive early momentum, we expect Saori-treated soybean seed to be planted on about 150,000 hectares next season, and many multiples of that amount over the next few years. Nutrien Ag Solutions is the very best partner for Saori, with multiple channels for making Saori available to Brazilian soybean growers. Saori is the first of many launches of products from the PREtec platform. We plan to launch PHC279 in the USA through our distributor, when regulatory permits have been obtained, expected in the second half of 2022. Thereafter, major PREtec product launches are planned each year. These launches underpin our confidence in Plant Health Care's growth projections for the coming years."

"Offering biological products is an important step to increasing the sustainability of Nutrien Ag Solution's product portfolio. As a company, we're looking for ways to make it easier for our customers to adopt sustainable practices on their lands, which is why we've invested a billion dollars into partnerships, research, and development into expanding our offerings of nature-based products," said Jeff Tarsi, Interim President of Global Retail, Nutrien Ag Solutions. "We're excited that we can partner with companies like Plant Health Care to bring more biological options for growers looking for alternatives to traditional synthetic products."

For further information, please contact:

 

Plant Health Care plc

Chris Richards, CEO

+1 919 926 1600

Cenkos Securities plc - Nomad & Broker

Neil McDonald / Pete Lynch

 +44 (0) 20 7391 8900

 

Vox Markets

Paul Cornelius / Kat Perez

+44 (0) 7866 384707

Nutrien Media Relations

Luciane Reis

Luciane.Reis@Nutrien.com

 

About Plant Health Care

Plant Health Care offers products to improve the health, vigour and yield of major field crops such as corn, soybeans, potatoes and rice, as well as specialty crops such as fruits and vegetables. We operate globally through subsidiaries, distributors and supply agreements with major industry partners. Our innovative, patent-protected biological products help growers to protect their crops from stress and diseases, and to produce higher quality fruit and vegetables, with a favourable environmental profile. Find out more at Vox Markets and the company website: www.planthealthcare.com

 

About Nutrien

Nutrien is the world's largest provider of crop inputs and services, playing a critical role in helping growers increase food production in a sustainable manner. We produce and distribute 27 million tonnes of potash, nitrogen and phosphate products world-wide. With this capability and our leading agriculture retail network, we are well positioned to supply the needs of our customers. We operate with a long-term view and are committed to working with our stakeholders as we address our economic, environmental and social priorities. The scale and diversity of our integrated portfolio provides a stable earnings base, multiple avenues for growth and the opportunity to return capital to shareholders. Nutrien Soluções Agrícolas is the retail business of Nutrien in Brazil, which has built a major presence through acquisitions and organic growth over the past decade.

 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRDGGDULGDDGDB
Date   Source Headline
16th Apr 20247:00 amRNSPlant Health Care--China Distribution with AMVAC
4th Apr 20247:00 amRNSApproval of PHC68949 in Mexico
4th Mar 20241:55 pmRNSHolding(s) in Company
24th Jan 20244:27 pmRNSHolding(s) in Company
2nd Jan 20247:00 amRNSBrazil approves TEIKKOâ„¢
20th Dec 20237:00 amRNSBoard Changes and Grant of Options
19th Dec 20233:34 pmRNSHolding(s) in Company
30th Nov 20231:45 pmRNSHolding(s) in Company
28th Nov 20233:16 pmRNSHolding(s) in Company
27th Nov 20234:03 pmRNSHolding(s) in Company
27th Nov 20231:27 pmRNSHolding(s) in Company
24th Nov 20234:19 pmRNSDirector/PDMR Shareholding
24th Nov 202310:57 amRNSDirector/PDMR Shareholding
23rd Nov 20232:31 pmRNSHolding(s) in Company
22nd Nov 20237:00 amRNSTrading Update
31st Oct 20237:00 amRNSChange of Adviser
20th Oct 20237:00 amRNSHolding(s) in Company
3rd Oct 20236:28 pmRNSPlant Health Care PREtec Product with Agrii UK
28th Sep 20237:00 amRNSNew PREtec Products Announced
27th Sep 20237:00 amRNSUnaudited Interim Results
25th Sep 20237:00 amRNSPREtec Products Submitted for Regulatory Approval
31st Aug 20237:00 amRNSNotice of Results & Investor Presentation
18th Aug 20237:00 amRNSNew Product Regulatory Approval In Brazil
1st Aug 20237:00 amRNSApproval for Sale of Harpin aß Granted in Poland
24th Jul 20237:00 amRNSGrant of Options
12th Jul 202312:27 pmRNSHolding(s) in Company
30th Jun 20235:07 pmRNSNotification of Major Holdings
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement
9th Jan 20237:00 amRNSInvestor Presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.